Deudomperidone
An investigational treatment for Gastroparesis.
The same compound appears under different names depending on the context. Here is how to identify Deudomperidone wherever you encounter it, plus the key facts at a glance.
- Generic name
- Deudomperidone
- Development code
- CIN-102
- Drug class
- Prokinetic (peripheral dopamine D2 receptor antagonist)
- Manufacturer
- CinDome Pharma (a CinRx company)
Deudomperidone (CIN-102) is an investigational medicine from CinDome Pharma built on domperidone, changed by deuteration and a new formulation. It has finished 2 Phase 2 gastroparesis trials, and the company expects topline results from the idiopathic gastroparesis trial in late 2026.
We'll email you when the FDA acts on Deudomperidone and when new trials for Gastroparesis open. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Gastroparesis. Turn any of these off from the link in every email.
How Deudomperidone works
CinDome describes deudomperidone as a new chemical entity based on deuteration and a novel formulation of domperidone[1]. Deuteration swaps some hydrogen atoms for deuterium, a heavier form of hydrogen, which can change how a drug is broken down in the body. Domperidone itself blocks dopamine receptors to help the stomach empty.
Mechanism: Deuterated, newly formulated form of domperidone, a dopamine D2 receptor blocker
Side effects and safety
No safety results from the 2 Phase 2 deudomperidone trials had been announced as of October 13, 2026. Domperidone, the medicine it is based on, carries FDA warnings about irregular heart rhythms and sudden death, and the trials' published results will show whether the modified form differs.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Clinical trial results
envision3D (NCT05832151) enrolled 382 adults with diabetic gastroparesis and was completed in December 2025, and envisionGI (NCT06899217) enrolled 416 adults with idiopathic gastroparesis and was completed in May 2026, according to ClinicalTrials.gov[3][4]. CinDome said in March 2026 that topline data from envisionGI are expected in late 2026[2]. We found no announced results from either trial as of October 13, 2026.
Development history
CinDome completed enrollment in envisionGI in March 2026[2]. Domperidone, the medicine it is based on, is not FDA-approved, and the FDA said its expanded access supply would end after September 2025.
Explore Gastroparesis trials
Other Gastroparesis treatments
Common questions about Deudomperidone
▸What is Deudomperidone?
Deudomperidone (CIN-102) is an investigational medicine from CinDome Pharma built on domperidone, changed by deuteration and a new formulation. It has finished 2 Phase 2 gastroparesis trials, and the company expects topline results from the idiopathic gastroparesis trial in late 2026.
▸How does Deudomperidone work?
CinDome describes deudomperidone as a new chemical entity based on deuteration and a novel formulation of domperidone[1]. Deuteration swaps some hydrogen atoms for deuterium, a heavier form of hydrogen, which can change how a drug is broken down in the body. Domperidone itself blocks dopamine receptors to help the stomach empty.
▸What are the side effects of Deudomperidone?
No safety results from the 2 Phase 2 deudomperidone trials had been announced as of October 13, 2026. Domperidone, the medicine it is based on, carries FDA warnings about irregular heart rhythms and sudden death, and the trials' published results will show whether the modified form differs.
▸Is Deudomperidone FDA approved?
Deudomperidone is currently in phase 2 clinical trials for Gastroparesis. It has not yet received FDA approval.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- CinDome Pharma. CinDome Pharma. https://www.cindome.com/
- CinDome Pharma, Business Wire · 2026-03-17. CinDome Pharma announces completion of enrollment in the envisionGI Phase 2 study of deudomperidone (CIN-102). https://www.businesswire.com/news/home/20260317651249/en
- ClinicalTrials.gov. CIN-102 in diabetic gastroparesis (envision3D). https://clinicaltrials.gov/study/NCT05832151
- ClinicalTrials.gov. CIN-102 in idiopathic gastroparesis (envisionGI). https://clinicaltrials.gov/study/NCT06899217